– USA, NJ – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of current Board member Jim Cashman as Chairman of the Board of Directors, effective as of December 1, 2021, succeeding Sherilyn McCoy, who is stepping down from the Board.
“I am excited to continue working with Jim as he assumes the role of Chairman. His proven track record at Ansys and passion for simulation-driven product development will help advance Certara’s innovation and global expansion.” said CEO, Dr. William Feehery.
About James E. Cashman III
James E. Cashman III has been a board member at Certara since 2018. He served for 20 years in the CEO and Executive Chairman roles at ANSYS, Inc., the global leader of engineering simulation software. Under his leadership, Ansys grew from $50 million to over $1 billion in revenue and was one of the top five public technology companies in total shareholder returns.
“I am honored to serve as Chairman of Certara’s Board. I am inspired by Certara’s cutting-edge biosimulation technology and its impact on improving the drug development process and patient outcomes,” said Jim Cashman. “I look forward to working closely with the Board, William, and the leadership team to create sustained value for all of Certara’s stakeholders.”
About Certara
Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
For more information: https://www.certara.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
